ASCO 2020 – Lung Cancer

Combination of Nivolumab, Ipilimumab, and Chemotherapy in Metastatic NSCLC

Combining nivolumab plus ipilimumab with 2 cycles of chemotherapy may be effective in patients undergoing first-line treatment for metastatic non–small-cell lung cancer.

3-Year Follow-Up Data for Nivolumab Combined with Ipilimumab in Treatment-Naïve NSCLC: CheckMate-227

After 3 years of follow-up, nivolumab combined with ipilimumab demonstrates sustained overall survival rates in treatment-naïve patients with advanced non–small-cell lung cancer.

CheckMate-9LA Evaluates Addition of Chemotherapy to NIVO + IPI in First-Line Advanced NSCLC

The addition of 2 cycles of chemotherapy to the combination of nivolumab and ipilimumab results in superior overall survival in treatment-naïve patients with advanced non–small-cell lung cancer.

Real-World Data for Nivolumab in Patients with Malignant Mesothelioma

Standard treatment for patients with advanced malignant pleural mesothelioma is predominantly chemotherapy-based. Nivolumab may be effective in these patients based on a retrospective real-world data assessment.

Immunotherapy Combined with Stereotactic Radiation in Early-Stage, Medically Inoperable NSCLC: Safety Analysis from I-SABR

Stereotactic ablative radiotherapy combined with immunotherapy (I-SABR) is well-tolerated in patients with early-stage, medically inoperable, isolated-recurrence non–small-cell lung cancer without lymph node or distant metastasis.

Meta-analysis of Checkpoint Inhibitor Trials in Front-Line NSCLC

Based on a meta-analysis of randomized trials in the first-line treatment of non–small-cell lung cancer, adding chemotherapy to immune checkpoint inhibitors (ICIs) improves response rates and progression-free survival in some patients compared with ICI monotherapy, but does not confer an overall survival benefit regardless of PD-L1 status.